Anthracycline- and taxane-based chemotherapy caused severe alopecia in up to 100% of breast cancer patients, with persistent hair loss in up to 67% for doxorubicin regimens.
What is the regimen-specific incidence, severity, and risk of persistent chemotherapy-induced alopecia in breast cancer patients?
Chemotherapy-induced alopecia, including persistent hair loss, is substantially more common than historically reported, particularly with anthracycline and taxane-based regimens.
Absolute Event Rate: 0% vs 0%
Chemotherapy-induced alopecia (CIA) is one of the most common and visible toxicities of breast cancer treatment, yet its true incidence, severity, and long-term outcomes remain inconsistently reported. Although CIA is frequently cited as affecting approximately 65% of patients and persistent alopecia has historically been considered uncommon (1–15%), emerging data suggest a substantially greater burden. We conducted a scoping review of PubMed, EMBASE, SCOPUS, and Cochrane databases to synthesize regimen-specific evidence on the incidence, severity, and persistence of CIA in breast cancer patients. Anthracycline- and taxane-based regimens were associated with the highest risk, with severe alopecia reported in more than 70% of patients and rates approaching 90–100% in combination regimens. Cyclophosphamide further amplified acute CIA when combined with doxorubicin, with reported incidence up to 93%. In contrast, capecitabine and vinorelbine were consistently associated with lower alopecia incidence. Importantly, CIA was not uniformly reversible. Persistent CIA (pCIA) occurred in up to 67% of patients treated with doxorubicin-based regimens and nearly 50% of those receiving docetaxel combinations, substantially higher than historically reported. Despite its high frequency and potential permanence, CIA remains underreported in oncology trials and insufficiently addressed in survivorship care. Recognizing CIA as both an acute toxicity and a potential long-term survivorship concern underscores the need for standardized reporting, longitudinal follow-up, and development of effective preventive strategies in breast cancer care.
Gaumond et al. (Sat,) reported a other. Anthracycline- and taxane-based chemotherapy caused severe alopecia in up to 100% of breast cancer patients, with persistent hair loss in up to 67% for doxorubicin regimens.